Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist

Cancer Research

Volumn 56, Issue 15, 1996, Pages 3486-3489

  Zia, Hasan ^a   Hida, Toyoaki ^a   Jakowlew, Sonia ^a   Birrer, Michael ^a   Gozes, Yehoshua ^b   Reubi, Jean C ^c   Fridkin, Mati ^d   Gozes, Illana ^e   Moody, Terry W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^c UNIVERSITY OF BERN   (Switzerland)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IODINE 125; MESSENGER RNA; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRID; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE C FOS; ONCOGENE C MYC; PRIORITY JOURNAL;

ANIMALS; BINDING SITES; BREAST NEOPLASMS; CELL DIVISION; CYCLIC AMP; FEMALE; GENES, FOS; HUMANS; IODINE RADIOISOTOPES; KINETICS; MICE; MICE, INBRED BALB C; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RNA, MESSENGER; TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0029684332     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Said, S. I. and Mutt, V. Polypeptide with broad biological activity isolation from the small intestine. Science (Washington DC), 69: 1217-1218, 1970.
2. Arimura, A. Pituitary adenylate cyclase activating polypeptide (PACAP): Discovery and current status of research. Regul. Pept., 37: 287-303, 1992.
3. Ishihara, T., Shigemoto, R. Mori, K., Takahashi, K., and Nagata, S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide Neuron. 8: 811-819, 1992.
4. Harmar, T., and Lutz, E. Multiple receptors for PACAP and VIP Trends Pharmacol. Sci., 15: 97-99, 1994.
5. Pisegna, J. R., and Wank, S. A. Molecular cloning and functional expression of the pituitary adenylate cyelase-activating polypeptide type I receptor Proc Natl. Acad. Sci. USA, 90: 6345-6349, 1993.
6. Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeberg, P. H., and Journot, L. Differential signal transduction by five splice variants-of the PACAP receptor Nature (Lond.), 365: 170-175, 1993.
7. Christophe, J., Chatelain, F., Taton, M., Delhaye, M., Waelbroeck, M., and Robberecht, P. Comparison of VIP-secretin receptors in rat and human lung Peptides, 2: 253-258, 1981.
8. Lee, M., Jensen, R. T., Huang, S. C., Bepler, G., Korman, L., and Moody, T. W. Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels. Peptides, 11: 1205-1209, 1990.
9. Moody, T. W., Zia, F., and Makheja, A. PACAP elevates cytosolic calcium in small cell lung cancer cell lines Peptides, 14: 241-246, 1993.
10. Pincus, D. W., DiCicco-Bloom, E. N., and Black, I. B. VIP regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature (Lond.), 343: 564-567, 1990.
11. Haegerstrand, A., Jonzon, B., Balsgaard, C. J., and Nilsson, J. Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA, 86: 5993-5996, 1986.
12. Maruno, and Said, S. I. Human small cell lung carcinoma inhibition by vasoactive intestinal peptide (VIP) and helodermin (Hd) Biomed. Res., 13: 373-375, 1993.
13. Brenneman, D. E., and Edten, L. E. Vasoactive intestinal peptide and electrical activity influence neuronal survival Proc. Natl. Acad. Sci. USA, 83: 1159-1162, 1986.
14. Moody, T. W., Zia, F., Brenneman, D., Fridkin, M., Davidson, A., and Gozes, I. A. VIP antagonist inhibits the growth of non-small cell lung cancer Proc. Natl. Acad. Sci. USA, 90: 4345-4349, 1993.
15. Gozes, I., McCune, S. K., Jacobson, L., Warren D., Moody, T. W., Fridkin, M., and Brenneman, D. E. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system J. Pharmacol. Exp. Ther., 257: 959-966, 1991.
16. Gozes Y., Brenneman, D. E., Fridkin, M., Asofsky, R., and Gozes, I. A. VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain Res., 540: 319-321, 1991.
17. Gozes, I., Davidson, M., Draoui, M., and Moody, T. W. The VIP gene is expressed in non-small cell lung cancer cell lines. Biomed Res, 13: 37-40, 1993.
18. Angelberger, P., Banyai, M., Banyai, S., Kurtaran, A., Li, S., Pidlich, J., Raderer, M., Virgolini, I., Yang, Q., Niederle, B., Scheithauer, W., and Valent, P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine rumors. N. Engl J. Med., 331: 1116-1121, 1994.
19. Gespach, C., Emami, S., and Rosselin, G. Gastric inhibitory peptide (GIP), pancreatic glucagon and vasoactive intestinal peptide (VIP) are cAMP inducing hormones in human gastric cancer cell line HGT-1: homologous desensitization of VIP receptor activity Biochem. Biophys. Res. Commun., 120: 641-649, 1984.
20. Bellan, C., Fabre, C., Luis, J., and Marvaldi, J. Pharmacological characterization of a new type of VIP receptor on the melanoma-derived cell Line IGR37. In G. Rosselin (ed.), Vasoactive Intestinal Peptide, Pituitary Adenylate Cyclase Activating Polypeptide & Related Regulatory Peptides From Molecular Biology to Clinical Applications, pp 179-186. Singapore World Scientific, 1994.
21. Li, M., Zheng, L. Q., Hoshino, M., Suzuki, M., Iguchi, K., Yanaihara, C., Mochizuki, T., and Yanihara, N. Helodermin receptors on human neuroblastoma NB-OK-1 cells In: G. Rosselin (ed.), Vasoactive Intestinal Peptide, Pituitary Adenylate Cyclase Activating Polypeptide & Related Regulatory Peptides: From Molecular Biology to Clinical Applications, pp. 173-178. Singapore: World Scientific, 1994.
22. Moody, T. W., Koros, A. M. C., Reubi, J. C., Naylor, P. H., and Goldstein, A. L. VIP analogues inhibit small cell lung cancer growth. Biomed. Res., 13: 131-136, 1993.
23. Shaffer, M. M., and Moody, T. W. Autoradiographic visualization of CNS receptors for vasoactive intestinal peptide. Peptides, 7: 283-288, 1986.
24. Chirgwin, J. M., Preybyla, A. E., MacDonald, R. J., and Rutter, W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18: 5294-5299, 1979.
25. Davis, L., Dibner, M., and Battey, J. F. Basic Methods in Molecular Biology. New York Elsevier, 1986.
26. Szabo, E., Preis, L. H., Brown, P. H., and Birrer, M. The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate-induced hemopoietic differentiation Cell Growth & Differ, 2: 475-482, 1993.
27. 1314] Bombesin analogues inhibit the growth of small cell lung cancer in vitro and in vivo Cancer Res., 51: 1798-1802, 1991.
28. Reubi, J. C. Neuropeptide receptors in health and disease the molecular basis for in vivo imaging J. Nucl. Med., 36: 1825-1835, 1995.
29. Reubi, J. C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging J. Nucl. Med., 36: 1846-1853, 1995.
30. Gespach, C., Bawab, W., DeCremoux, P., and Calvo, F. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells Cancer Res., 48: 5079-5083, 1988.
31. Slamon, D. J., Godophin, W., and Jones, L. A. Studies of the HER-2/NEU proto-oncogene in human breast and ovarian cancer Science (Washington DC), 244: 707-712, 1989.
32. Gullick, W. J. The role of the epidermal growth factor receptor and the c-ERBB-2 protein in breast cancer. Int. J. Cancer, 55: 66-71, 1990.
33. Cullen, K. J. Yee, D., Sly, W. S., Perdue, J., Hampton, B., Lippman, M. E., and Rosen, N. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res., 50: 48-53, 1990.
34. Artega, C. L., and Osborne, C. K. Growth inhibition of human breast cancer cells in vitro with an antibody against type I somatomedin receptor Cancer Res., 49: 6237-6241, 1989.
35. Soule, H. D., Vazquez, J., Long, A., Albert, S., and Brennan, M. A. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst., 51: 1409-1416, 1973.
36. Calvo, F., Brower, M., and Carney, D. N. Continuous culture and soft agarose cloning of multiple human breast carcinoma cell lines in serum-free medium. Cancer Res., 44: 4553-4559, 1984.
37. Harris, J. R., Morrow, M., and Bonadonna, G. Cancer of the Breast. Cancer: Principles & Practice of Oncology, pp. 1264-1332 In: V. T. DeVita, A. Hellman, and S. A. Rosenberg (eds.), Philadelphia J P Lippincott Co, 1993.